Distinctive germline expression of class I human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade

Distinctive germline expression of class I human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade

Background Nivolumab is a human monoclonal antibody against programmed cell death receptor-1 (PD-1) able to rescue quiescent tumor infiltrating cytotoxic T lymphocytes (CTLs) restoring their ability to kill target cells expressing specific tumor antigen-derived epitope peptides bound to homologue hu...

Full description

Bibliographic Details
Main Authors: Rita Emilena Saladino, Rocco Giannicola, Rita Agostino, Nicoletta Staropoli, Alessandra Strangio, Teresa Del Giudice, Maria Altomonte, Paolo Tini, Antonia Consuelo Falzea, Natale Imbesi, Valentina Arcati, Giuseppa Romeo, Daniele Caracciolo, Amalia Luce, Michele Caraglia, Antonio Giordano, Alois Necas, Evzen Amler, Vito Barbieri, Pierfrancesco Tassone
Format: Article
Language:English
Published: BMJ Publishing Group 2020-06-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/8/1/e000733.full

Similar Items

Similar Items